CLOs on the Move

BridgeBio

www.bridgebio.com

 
We are a collection of individuals focused on discovering and developing drugs for patients with grievous genetic diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Thomas Trimarchi
President and Chief Financial Officer Profile
Laura Woodhead
SVP, Deputy General Counsel Profile
Adora Ndu
Chief Regulatory Officer and EVP Profile
Matty Taga-Allen
Vice President, People Operations, Compliance and Executive HRBP Profile
Christine Liu
Vice President, Legal Profile

Similar Companies

Affigen

Affigen was founded in 2016 by Frameshift, a firm that ideates, translates and launches life sciences companies that have the potential to fundamentally shift the metabolic rate of the industry. In February 2017, Affigen completed its Series A funding, led by Black Beret Life Sciences on behalf of its affiliate BBLS Immunotherapy, LLC. Black Beret Life Sciences is the life sciences investment management arm of the Houston-based Bosarge Family Office. The firm was established in 2014 by Dr. Ed Bosarge to organize and manage investments in potentially game-changing technologies and companies in areas related to regenerative medicine, anti-aging and immunotherapy. Black Beret Life Sciences’ portfolio of managed investments includes companies and research across an array of disease areas, including diabetes, neurodegeneration, osteoarthritis, cancer immunotherapy and various conditions related to aging.

Nacalai USA

Nacalai USA is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Stericide

Stericide is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Verge Genomics

We are pioneering a better drug discovery process using systems biology to improve the lives of people with neurodegenerative disorders.

Apple Valley Chamber-commerce

Apple Valley Chamber-commerce is a Apple Valley, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.